Background: Rheumatoid arthritis (RA) in elderly population represents a challenge for physicians in terms of therapeutic management. Methotrexate (MTX) is the first-line treatment among conventional synthetic-disease-modifying anti-rheumatic drugs (cs-DMARDs); however, it is often associated with adverse events (AEs). Therefore, the objective of this study was to identify the incidence and risk factors of MTX discontinuation due to AEs in elderly patients with RA in a long-term retrospective cohort study. Methods: Clinical sheets from elderly RA patients taking MTX from an outpatient rheumatology consult in a university centre were reviewed. To assess MTX persistence, we used Kaplan–Meir curves and Cox regression models to identify the risk of withdrawing MTX due to adverse events. Results: In total, 198 elderly RA patients who reported using MTX were included. Of them, the rates of definitive suspension of MTX due to AEs were 23.0% at 5 years, 35.6% at 10 years and 51.7% at 15 years. The main organs and system involved were gastrointestinal (15.7%) and mucocutaneous (3.0%). Factors associated with withdrawing MTX due to AEs were MTX dose ≥ 15 mg/wk (adjusted HR: 2.46, 95% CI: 1.22–4.96, p = 0.012); instead, the folic acid supplementation was protective for withdrawal (adjusted HR: 0.28, 95% CI: 0.16–0.49, p < 0.001). Conclusions: Higher doses of MTX increase the risk of withdrawals in elderly RA, while folic acid supplementation reduces the risk. Therefore, physicians working in therapeutic management for elderly patients using MTX must focus on using lower MTX doses together with the concomitant prescription of folic acid.

Urinary tract infections (UTIs) constitute one of the main complications in kidney recipients, increasing both morbidity and mortality. Due to the resurgence of antimicrobial resistance, new prophylactic approaches are being investigated. Nitrofurantoin is an antibiotic from the nitrofuran group that is effective against several Gram-negative and Gram-positive organisms; hence, there has been a resurgence in its prescription for treating MDR pathogens. Objectives: This study aims to assess the effectiveness of nitrofurantoin as an add-on to conventional therapy (amikacin + ceftriaxone or cefotaxime) for the treatment of urinary tract infections in kidney recipients. Methods: In a prospective cohort study, we included patients who received a kidney in a tertiary-care hospital. According to the intensive care specialist, group 1 patients were treated with the conventional prophylactic treatment plus nitrofurantoin as an add-on. Group 2 patients were treated only with the conventional prophylactic treatment. They were followed-up for 3 months, and the incidence of urinary tract infections was reported. Results: The UTI incidence for group 1 at 3 months was 20.6%, and for group 2, it was 20.0%; no statistical difference between treatments was observed (p = 0.9). The most commonly isolated pathogens were E. coli (28.5) and K. pneumonie (28.5%). The factor most associated with developing a UTI was female gender (aHR: 7.0; 95% IC 2.3–20.9, p < 0.001). Conclusions: In our cohort study, nitrofurantoin as an add-on in conventional therapy did not prove to be effective in preventing UTI development; therefore, other treatment options should be considered as a part of prophylactic treatment.

Background/Objectives: Depression is a mood disorder characterized by persistent sadness and loss of interest. Pharmacy students exhibit a relatively high prevalence of depressive symptoms, which may negatively impact quality of life, academic performance, and, in severe cases, lead to suicidal ideation. Given the increasing trend of medication use among young adults, we hypothesized that this behavior may be associated with depressive symptoms, potentially reflecting attempts to manage concurrent physical symptoms or reduced psychological well-being. Therefore, the objective of this study was to assess the association between depressive symptoms and medication use among pharmacy students. Methods: A cross-sectional study was conducted among students enrolled in pharmacy-related programs from University Center for Exact Sciences and Engineering (CUCEI), University of Guadalajara. Participants completed a personalized questionnaire assessing sociodemographic variables, medication use, comorbid conditions, and depressive symptoms using the Patient Health Questionnaire-9. Descriptive statistics were used to summarize participant characteristics. Categorical variables were reported as frequencies and percentages and compared using the chi-square test. Continuous variables were summarized as means and standard deviations and compared using Student t-test. To evaluate factors associated with moderate-to-severe depressive symptoms, logistic regression and multivariable linear regression analyses were performed. Results: A total of 365 students completed our personalized questionnaire; nearly half of the sample (47.3%) presented moderate-to-severe depressive symptoms. Multivariable analyses showed that insufficient sleep, academic stress, psychological support, and the number of medications used simultaneously were significantly associated with depressive symptoms. Logistic regression identified being in a relationship and receiving psychological support for at least one year as protective factors, while employment, insufficient sleep, academic stress, and a greater number of concomitant medications were associated with increased odds of moderate-to-severe depressive symptoms. Conclusions: A modest association was observed between self-reported medication use and moderate-to-severe depressive symptoms among pharmacy students. These findings suggest that medication use patterns may warrant further investigation as a potential marker of depressive symptoms in pharmacy students. Future longitudinal studies are needed to clarify the nature and direction of this association and to determine whether medication use could contribute to the identification of students at increased risk of depression.

Background: Every year, 1.5 million women worldwide experience menopause and the associated changes that cause disability and dysfunction. There are multiple treatments focused on the symptoms; hormone replacement therapy (HRT) may be one that helps us reduce these changes. Objectives: the objective of this work was to assess the relationship between skeletal muscle mass and bone mineral density in postmenopausal women using hormone replacement therapy. Methods: Study design: cross-sectional study. A systematic assessment of clinical charts from postmenopausal women using hormone replacement therapy. Differences between low muscle mass and low bone mineral density were assessed; linear regression models were calculated to estimated the effect of body mass index, length of menopause, age, presence of comorbidities, physical activity and muscle mass have over those variables. Results: Bone mineral density was heavily influenced level of body mass index (aẞ: 0.015, 95% CI, 0.010, 0.019, p<0.001) and age (aẞ: -0.006, 95% CI, -0.010, -0.002, p=0.002); while muscle mass changes were associated with body mass index (aẞ: 0.548, 95% CI, 0.456, 0.640, p<0.001) and Age (aẞ: -0.081, 95% CI, -0.155, -0.006, p=0.034) Conclusions: The use of Hormone replacement therapy does not have a relation with the levels of muscle mass neither bone mineral density in postmenopausal women.